{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:07:31Z","timestamp":1789452451287,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11030-025-11195-6","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T12:45:25Z","timestamp":1745930725000},"page":"101-112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["GLP-1R agonists: recent advances, current gaps, and future challenges"],"prefix":"10.1007","volume":"30","author":[{"given":"Anukriti","family":"Saran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya","family":"Raisinghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarvesh","family":"Paliwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"11195_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.obmed.2024.100545","author":"M Agosta","year":"2024","unstructured":"Agosta M, Sofia M, Pezzino S, D\u2019Amato S, Litrico G, Mazzone C, Greca GL, Latteri S (2024) Efficacy of liraglutide in pediatric obesity: a review of clinical trial data. Obesity Med. https:\/\/doi.org\/10.1016\/j.obmed.2024.100545","journal-title":"Obesity Med"},{"key":"11195_CR2","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee (2024) 10. Cardiovascular disease and risk management: standards of care in diabetes\u20142024. Diabetes Care 47(Suppl 1):S179\u2013S218. https:\/\/doi.org\/10.2337\/dc24-S010","DOI":"10.2337\/dc24-S010"},{"key":"11195_CR3","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee (2024) 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes\u20142024. Diabetes Care 47(Suppl 1):S158\u2013S178. https:\/\/doi.org\/10.2337\/dc24-S009","DOI":"10.2337\/dc24-S009"},{"issue":"10296","key":"11195_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH (2021) SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet (London, England) 398(10296):262\u2013276. https:\/\/doi.org\/10.1016\/S0140-6736(21)00536-5","journal-title":"Lancet (London, England)"},{"issue":"10437","key":"11195_CR5","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","volume":"403","author":"J Butler","year":"2024","unstructured":"Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstr\u00f8m SZ, Davies MJ, Hovingh GK, Kitzman DW, M\u00f8ller DV, Verma S, Einfeldt MN, Lindegaard ML, Rasmussen S, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H et al (2024) Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet (London, England) 403(10437):1635\u20131648. https:\/\/doi.org\/10.1016\/S0140-6736(24)00469-0","journal-title":"Lancet (London, England)"},{"issue":"6","key":"11195_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13177","volume":"22","author":"KR Chadda","year":"2021","unstructured":"Chadda KR, Cheng TS, Ong KK (2021) GLP-1 agonists for obesity and type 2 diabetes in children: Systematic review and meta-analysis. Obes Rev 22(6):e13177. https:\/\/doi.org\/10.1111\/obr.13177","journal-title":"Obes Rev"},{"issue":"Suppl 1","key":"11195_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jcpt.13230","volume":"45","author":"S Cornell","year":"2020","unstructured":"Cornell S (2020) A review of GLP-1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once-weekly agents. J Clin Pharm Ther 45(Suppl 1):17\u201327. https:\/\/doi.org\/10.1111\/jcpt.13230","journal-title":"J Clin Pharm Ther"},{"key":"11195_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000001214","author":"TA Costa","year":"2025","unstructured":"Costa TA, Harrington JL (2025) Advances in the management of obesity and heart failure: latest evidence from clinical trials. Curr Opin Cardiol. https:\/\/doi.org\/10.1097\/HCO.0000000000001214","journal-title":"Curr Opin Cardiol"},{"key":"11195_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/alz.057848","author":"P Edison","year":"2021","unstructured":"Edison P, Femminella GD, Ritchie CW, Holmes C, Walker Z, Ridha BH, Raza S, Livingston NR, Nowell J, Busza G, Frangou E, Love S, Williams G, Lawrence RM, McFarlane B, Archer H, Coulthard E, Underwood B, Koranteng P, Karim S, Bannister C et al (2021) Evaluation of liraglutide in the treatment of Alzheimer\u2019s disease. Alzheimers Dementia. https:\/\/doi.org\/10.1002\/alz.057848","journal-title":"Alzheimers Dementia"},{"issue":"1","key":"11195_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/bph.12895","volume":"172","author":"H Fan","year":"2015","unstructured":"Fan H, Gong N, Li TF, Ma AN, Wu XY, Wang MW, Wang YX (2015) The non-peptide GLP-1 receptor agonist WB4-24 blocks inflammatory nociception by stimulating \u03b2-endorphin release from spinal microglia. Br J Pharmacol 172(1):64\u201379. https:\/\/doi.org\/10.1111\/bph.12895","journal-title":"Br J Pharmacol"},{"issue":"3\u20134","key":"11195_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","volume":"11","author":"TD Filippatos","year":"2014","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS (2014) Adverse effects of GLP-1 receptor agonists. Rev Diabetic Stud RDS 11(3\u20134):202\u2013230. https:\/\/doi.org\/10.1900\/RDS.2014.11.202","journal-title":"Rev Diabetic Stud RDS"},{"issue":"6","key":"11195_CR12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa2407379","volume":"392","author":"CK Fox","year":"2025","unstructured":"Fox CK, Barrientos-P\u00e9rez M, Bomberg EM, Dcruz J, Gies I, Harder-Lauridsen NM, Jalaludin MY, Sahu K, Weimers P, Zueger T, Arslanian S, SCALE Kids Trial Group (2025) Liraglutide for children 6 to <12 years of age with obesity\u2014a randomized trial. New Engl J Med 392(6):555\u2013565. https:\/\/doi.org\/10.1056\/NEJMoa2407379","journal-title":"New Engl J Med"},{"issue":"Pt 3","key":"11195_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1113\/jphysiol.2005.098962","volume":"569","author":"A Gameiro","year":"2005","unstructured":"Gameiro A, Reimann F, Habib AM, O\u2019Malley D, Williams L, Simpson AK, Gribble FM (2005) The neurotransmitters glycine and GABA stimulate glucagon-like peptide-1 release from the GLUTag cell line. J Physiol 569(Pt 3):761\u2013772. https:\/\/doi.org\/10.1113\/jphysiol.2005.098962","journal-title":"J Physiol"},{"issue":"4","key":"11195_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/jcm9040947","volume":"9","author":"JL G\u00f3rriz","year":"2020","unstructured":"G\u00f3rriz JL, Soler MJ, Navarro-Gonz\u00e1lez JF, Garc\u00eda-Carro C, Puchades MJ, D\u2019Marco L, Mart\u00ednez Castelao A, Fern\u00e1ndez-Fern\u00e1ndez B, Ortiz A, G\u00f3rriz-Zambrano C, Navarro-P\u00e9rez J, Gorgojo-Martinez JJ (2020) GLP-1 receptor agonists and diabetic kidney disease: a call of attention to nephrologists. J Clin Med 9(4):947. https:\/\/doi.org\/10.3390\/jcm9040947","journal-title":"J Clin Med"},{"issue":"3","key":"11195_CR15","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.3892\/etm.2020.8714","volume":"20","author":"RA Iorga","year":"2020","unstructured":"Iorga RA, Bacalbasa N, Carsote M, Bratu OG, Stanescu AMA, Bungau S, Pantis C, Diaconu CC (2020) Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review). Exp Ther Med 20(3):2396\u20132400. https:\/\/doi.org\/10.3892\/etm.2020.8714","journal-title":"Exp Ther Med"},{"issue":"2","key":"11195_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13731","volume":"75","author":"AB Jain","year":"2021","unstructured":"Jain AB, Ali A, Gorgojo Mart\u00ednez JJ, Hramiak I, Kavia K, Madsbad S, Potier L, Prohaska BD, Strong JL, Vilsb\u00f8ll T (2021) Switching between GLP-1 receptor agonists in clinical practice: expert consensus and practical guidance. Int J Clin Pract 75(2):e13731. https:\/\/doi.org\/10.1111\/ijcp.13731","journal-title":"Int J Clin Pract"},{"issue":"4","key":"11195_CR17","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/bph.15497","volume":"179","author":"B Jones","year":"2022","unstructured":"Jones B (2022) The therapeutic potential of GLP-1 receptor biased agonism. Br J Pharmacol 179(4):492\u2013510. https:\/\/doi.org\/10.1111\/bph.15497","journal-title":"Br J Pharmacol"},{"issue":"10456","key":"11195_CR18","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, Emerson SS, Kahn SE, Kitzman DW, Lingvay I, Mahaffey KW, Petrie MC, Plutzky J, Rasmussen S, R\u00f6nnb\u00e4ck C, Shah SJ, Verma S, Weeke PE, Lincoff AM, SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM Trial Committees and Investigators (2024) Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet (London, England) 404(10456):949\u2013961. https:\/\/doi.org\/10.1016\/S0140-6736(24)01643-X","journal-title":"Lancet (London, England)"},{"issue":"11","key":"11195_CR19","doi-asserted-by":"publisher","first-page":"9324","DOI":"10.3390\/ijms24119324","volume":"24","author":"HA Lee","year":"2023","unstructured":"Lee HA, Kim HY (2023) Therapeutic mechanisms and clinical effects of glucagon-like peptide 1 receptor agonists in nonalcoholic fatty liver disease. Int J Mol Sci 24(11):9324. https:\/\/doi.org\/10.3390\/ijms24119324","journal-title":"Int J Mol Sci"},{"issue":"3","key":"11195_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.diabres.2011.01.004","volume":"93","author":"M Marre","year":"2011","unstructured":"Marre M, Penfornis A (2011) GLP-1 receptor agonists today. Diabetes Res Clin Pract 93(3):317\u2013327. https:\/\/doi.org\/10.1016\/j.diabres.2011.01.004","journal-title":"Diabetes Res Clin Pract"},{"key":"11195_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR, D\u2019Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ et al (2019) Glucagon-like peptide 1 (GLP-1). Molecular Metabolism 30:72\u2013130. https:\/\/doi.org\/10.1016\/j.molmet.2019.09.010","journal-title":"Molecular Metabolism"},{"key":"11195_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art. Mol Metab 46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"issue":"11","key":"11195_CR23","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s11883-022-01062-2","volume":"24","author":"MR Pedrosa","year":"2022","unstructured":"Pedrosa MR, Franco DR, Gieremek HW, Vidal CM, Bronzeri F, de Cassia Rocha A, de Carvalho Cara LG, Fogo SL, Eliaschewitz FG (2022) GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far? Curr Atheroscler Rep 24(11):867\u2013884. https:\/\/doi.org\/10.1007\/s11883-022-01062-2","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"11195_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R, FLOW Trial Committees Investigators (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 391(2):109\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"},{"issue":"13","key":"11195_CR25","doi-asserted-by":"publisher","first-page":"10449","DOI":"10.3390\/ijms241310449","volume":"24","author":"MS Popoviciu","year":"2023","unstructured":"Popoviciu MS, P\u0103duraru L, Yahya G, Metwally K, Cavalu S (2023) Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials. Int J Mol Sci 24(13):10449. https:\/\/doi.org\/10.3390\/ijms241310449","journal-title":"Int J Mol Sci"},{"key":"11195_CR26","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212283","volume":"4","author":"L Prasad-Reddy","year":"2015","unstructured":"Prasad-Reddy L, Isaacs D (2015) A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context 4:212283. https:\/\/doi.org\/10.7573\/dic.212283","journal-title":"Drugs Context"},{"issue":"1","key":"11195_CR27","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1021\/acsomega.8b03052","volume":"4","author":"T Redij","year":"2019","unstructured":"Redij T, Chaudhari R, Li Z, Hua X, Li Z (2019) Structural modeling and in silico screening of potential small-molecule allosteric agonists of a glucagon-like peptide 1 receptor. ACS Omega 4(1):961\u2013970. https:\/\/doi.org\/10.1021\/acsomega.8b03052","journal-title":"ACS Omega"},{"issue":"1","key":"11195_CR28","doi-asserted-by":"publisher","first-page":"19041","DOI":"10.1038\/s41598-023-46274-x","volume":"13","author":"HM Salamah","year":"2023","unstructured":"Salamah HM, Marey A, ElSayed E, Hasan MT, Mahmoud A, Abualkhair KA, Abo-Elnour DE, Abdelhaleem IA, Abd-Elgawad M (2023) Efficacy and safety of polyethylene glycol loxenatide in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Sci Rep 13(1):19041. https:\/\/doi.org\/10.1038\/s41598-023-46274-x","journal-title":"Sci Rep"},{"issue":"7","key":"11195_CR29","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","volume":"30","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML (2024) Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med 30(7):2037\u20132048. https:\/\/doi.org\/10.1038\/s41591-024-03018-2","journal-title":"Nat Med"},{"key":"11195_CR30","unstructured":"Saran A, Kumari P, Arya K, Sharma S, Paliwal S (2024) Key modifiers of glucose metabolism associated diseases (GMADs): a mini review. YMER. https:\/\/ymerdigital.com\/uploads\/YMER230430.pdf"},{"issue":"6","key":"11195_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/14779072.2024.2363395","volume":"22","author":"R Sato","year":"2024","unstructured":"Sato R, von Haehling S (2024) Targeting obesity for therapeutic intervention in heart failure patients. Expert Rev Cardiovasc Ther 22(6):217\u2013230. https:\/\/doi.org\/10.1080\/14779072.2024.2363395","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"6","key":"11195_CR32","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/dom.14675","volume":"24","author":"M Schechter","year":"2022","unstructured":"Schechter M, Fischer M, Mosenzon O (2022) Preventing all-cause hospitalizations in type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a narrative review and proposed clinical approach. Diabetes Obes Metab 24(6):969\u2013982. https:\/\/doi.org\/10.1111\/dom.14675","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"11195_CR33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/19322968241291512","volume":"19","author":"VN Shah","year":"2025","unstructured":"Shah VN, Peters AL, Umpierrez GE, Sherr JL, Akturk HK, Aleppo G, Bally L, Cengiz E, Cinar A, Dungan K, Fabris C, Jacobs PG, Lal RA, Mader JK, Masharani U, Prahalad P, Schmidt S, Zijlstra E, Ho CN, Ayers AT et al (2025) Consensus report on glucagon-like peptide-1 receptor agonists as adjunctive treatment for individuals with type 1 diabetes using an automated insulin delivery system. J Diabetes Sci Technol 19(1):191\u2013216. https:\/\/doi.org\/10.1177\/19322968241291512","journal-title":"J Diabetes Sci Technol"},{"key":"11195_CR34","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","volume":"108","author":"D Sharma","year":"2018","unstructured":"Sharma D, Verma S, Vaidya S, Kalia K, Tiwari V (2018) Recent updates on GLP-1 agonists: current advancements & challenges. Biomed Pharmacother 108:952\u2013962. https:\/\/doi.org\/10.1016\/j.biopha.2018.08.088","journal-title":"Biomed Pharmacother"},{"issue":"1133","key":"11195_CR35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/postgradmedj-2019-137186","volume":"96","author":"KH Sheahan","year":"2020","unstructured":"Sheahan KH, Wahlberg EA, Gilbert MP (2020) An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad Med J 96(1133):156\u2013161. https:\/\/doi.org\/10.1136\/postgradmedj-2019-137186","journal-title":"Postgrad Med J"},{"issue":"3","key":"11195_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11154-014-9287-7","volume":"15","author":"J Skov","year":"2014","unstructured":"Skov J (2014) Effects of GLP-1 in the kidney. Rev Endocr Metab Disord 15(3):197\u2013207. https:\/\/doi.org\/10.1007\/s11154-014-9287-7","journal-title":"Rev Endocr Metab Disord"},{"key":"11195_CR37","doi-asserted-by":"publisher","first-page":"204201882199732","DOI":"10.1177\/2042018821997320","volume":"12","author":"JM Trujillo","year":"2021","unstructured":"Trujillo JM, Nuffer W, Smith BA (2021) GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab 12:2042018821997320. https:\/\/doi.org\/10.1177\/2042018821997320","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"10479","key":"11195_CR38","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","volume":"405","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene SS, Hibbert S, Wong A, Melander S, Gibson R, Matthews H, Dickson J, Carroll C, Patrick A, Inches J, Silverdale M, Blackledge B, Whiston J, Hu M, Welch J et al (2025) Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet (London, England) 405(10479):627\u2013636. https:\/\/doi.org\/10.1016\/S0140-6736(24)02808-3","journal-title":"Lancet (London, England)"},{"issue":"8","key":"11195_CR39","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/dom.14032","volume":"22","author":"KH Yoon","year":"2020","unstructured":"Yoon KH, Kang J, Kwon SC, Trautmann ME, Hompesch M, Stewart J, Sorli CH (2020) Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes. Diabetes Obes Metab 22(8):1292\u20131301. https:\/\/doi.org\/10.1111\/dom.14032","journal-title":"Diabetes Obes Metab"},{"key":"11195_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.721135","volume":"12","author":"X Zhao","year":"2021","unstructured":"Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, Xue H, Liu Y, Zhang Y (2021) GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol 12:721135. https:\/\/doi.org\/10.3389\/fendo.2021.721135","journal-title":"Front Endocrinol"},{"issue":"1","key":"11195_CR41","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther 9(1):234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z","journal-title":"Signal Transduct Target Ther"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11195-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11195-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11195-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T15:56:58Z","timestamp":1771775818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11195-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["11195"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11195-6","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As this submission is a review article ,it  does not involve humans and animals, and no ethical approval was required for this publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}